DBV Technologies Declares Departure of Board Member
DBV Technologies Announces Resignation of Board Member and Proposed New Appointee
DBV Technologies, a clinical-stage biopharmaceutical company focused on developing treatment options for food allergies and other immunologic conditions, has announced the resignation of Daniel Soland, a member of its Board of Directors. The resignation is effective immediately.
The company is committed to transforming the care of food allergic people, and is currently investigating the use of its proprietary VIASKIN® patch technology to address food allergies. VIASKIN® is a registered trademark of DBV Technologies and is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin.
In light of Mr. Soland's resignation, DBV Technologies has proposed Berthold Krebs to fill the vacant position on the Supervisory Board. Mr. Krebs brings a wealth of experience in the pharmaceutical industry, and the company believes he will be a valuable addition to the Board.
DBV Technologies' Board of Directors will continue to operate with 9 remaining members. The company will evaluate the appropriate timing and process for the provisional appointment of a new member to fill Mr. Soland's vacancy.
For more information about DBV Technologies, visit www.dbv-technologies.com. For media inquiries, contact Brett Whelan at [email protected]. For investor inquiries, contact Katie Matthews at [email protected].
DBV Technologies' American Depositary Shares (ADSs) are traded on the Nasdaq Capital Market (DBVT - CUSIP: 23306J309). The company's ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345).
DBV Technologies has its headquarters in Chațillon, France, with North American operations in Warren, NJ. The company encourages engagement on X (formerly Twitter) and LinkedIn.
[Attachment available for this press release]
Michel de Rosen is the Chairman of the Board of DBV Technologies. DBV Technologies is focused on developing treatment options for food allergies and other immunologic conditions, and is dedicated to improving the lives of those affected by these conditions.
Read also:
- Strategies for Increasing Food Intake in Advanced Years
- Drug-resistant pathogens prevalent across ICDDR,B, posing a considerable risk to newborns.
- Difficulties with Access to Care Highlighted in Prudential Asia Healthcare Survey 2025, Revealing Patient Concerns
- Veteran Nightmares Alleviated Through NightWare Technology on Apple Watch
